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A murine erythroleukemogenic retrovirus, Friend spleen focus-forming virus, encodes an envelope protein-like membrane
glycoprotein (gp55) in its defective env gene which is responsible for activation of the erythropoietin receptor (EpoR) and the
abnormally rapid proliferation of erythroid precursor cells. The S34 mutant gp55, which possesses an additional cytoplasmic
domain, is nonpathogenic and its processing to the cell surface is severely reduced compared to that of the wild-type gp55.
In this study, we found that the S34 mutant gp55 neither binds to nor activates the EpoR. The S34 mutant gp55 formed
disulfide-bonded homodimers in the rough endoplasmic reticulum (RER) membrane much less efficiently than the wild-type
gp55, which is consistent with the proposal that homodimer formation is a prerequisite for gp55 to be exported from the RER.
We found that the wild-type gp55 that is bound to EpoR in the RER consists of a large number of monomers and a small
number of dimers, suggesting that monomers of the S34 mutant gp55 have lost the ability to bind to the EpoR. The 1-bp
insertion present in the wild-type gp55 gene, causing a loss of the cytoplasmic domain, is essential for pathogenicity in that
it renders the encoded protein capable of both binding to the EpoR and transport to the cell surface. © 1998 Academic Press
INTRODUCTION
Friend spleen focus-forming virus (F-SFFV) is a repli-
cation-defective erythroleukemogenic mouse retrovirus
and encodes an envelope protein (Env)-like membrane
glycoprotein with a molecular mass of 52–55 kDa (gp55)
in its defective env gene. Gp55 is responsible for an
abnormally rapid proliferation of erythroid precursor cells
in adult mice of susceptible strains which have been
infected with the Friend virus complex, consisting of
F-SFFV and a helper Friend murine leukemia virus (F-
MuLV) (Kabat, 1989; Ruscetti, 1995). Friend viral erythro-
leukemia is a multistep progressive disease which is
conventionally divided into two stages. In the early stage,
erythroid hyperplasia is evident in the bone marrow and
spleen of the infected mouse due to the expression of
F-SFFV gp55 and results in splenomegaly and polycythe-
mia (or anemia). In the late stage of the disease, several
additional cytogenetic changes cause leukemic transfor-
mation of proliferating erythroblast cells (Ben-David and
Bernstein, 1991).
The primary structure of gp55 is very similar to those
of env proteins of polytropic (dualtropic) MuLVs
(Amanuma et al., 1983; Clark and Mak, 1983; Wolff et al.,
1983). Gp55 is, however, not incorporated into virions but
mostly stays inside the cells, mainly in the rough endo-
plasmic reticulum (RER) membrane as a glycoprotein
with only high-mannose-type oligosaccharide chains. A
few percent of gp55 molecules are processed through
the Golgi apparatus, which modifies the oligosaccharide
chains, and the gp55 molecules appear on the cell sur-
face as a plasma membrane form (gp55P) (Ruta et al.,
1982; Srinivas and Compans, 1983). The extracytoplas-
mic domain of this higher molecular weight form of gp55
is then released from the cells after proteolytic cleavage
from the transmembrane domain (Gliniak and Kabat,
1989; Pinter and Honnen, 1989). In vitro factor-indepen-
dent cell proliferation assay has shown that gp55 of the
polycythemia-inducing isolate of F-SFFV (F-SFFVp) spe-
cifically associates with the mouse erythropoietin recep-
tor (EpoR) and activates it to initiate mitogenic signal
transduction (Li et al., 1990; Yoshimura et al., 1990).
Various lines of genetic and biochemical evidence indi-
cated that the complex formation of gp55P with EpoR at
the cell surface is essential for EpoR activation (Ferro et
al., 1993; Wang et al., 1993; Li et al., 1995). Activation of
EpoR by gp55 is consistent with its involvement in the
abnormal proliferation of erythroid precursor cells in vivo,
in which EpoR is expressed and responsible for growth
and differentiation of precursor cells to erythrocytes.
We have been interested in the primary structure of
gp55 which is required for its biological activity in vivo
(Amanuma et al., 1989; Watanabe et al., 1990, 1991, 1995;
Yugawa and Amanuma, 1998). Previously we described a
series of mutant gp55s which differ from the wild-type
gp55 in the 6-amino-acid sequence of the transmem-
brane domain and in the cytoplasmic domain (Watanabe
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et al., 1995). The wild-type gp55 has no cytoplasmic
domain due to the presence of a 1-bp insertion in its
gene in the region which normally encodes the trans-
membrane domain of the MuLV env protein (p15E). Mu-
tant gp55, on the other hand, possesses a varying size of
cytoplasmic domain, whose amino acid sequence is
derived from the cytoplasmic domain of the MuLV env
protein. Depending on the size of the cytoplasmic do-
main, F-SFFV encoding the mutant gp55 showed a vary-
ing degree of pathogenicity and mutant gp55s in general
demonstrated reduced processing to the cell surface
from the wild-type protein, as evidenced by the de-
creased amount of the processed higher molecular
weight form. One of these mutant gp55s, the S34 mutant
gp55, has a 34-amino-acid cytoplasmic domain con-
nected to intact extracytoplasmic and transmembrane
domains. F-SFFV encoding the S34 mutant gp55 showed
no pathogenicity in mice.
In the present study, we asked whether the S34 mutant
gp55 activates EpoR in an in vitro factor-independent cell
proliferation assay and whether this mutant protein binds
to the EpoR. We also analyzed the disulfide-bonded ho-
modimer formation of the mutant protein in the RER,
since the specific type of homodimer was suggested to
be competent for transport to the cell surface in the case
of the wild-type gp55 (Gliniak and Kabat, 1989; Kilpatrick
et al., 1989). The results indicated that the S34 mutant
gp55 does not activate nor bind to the EpoR and showed
a lower level of homodimer formation than the wild-type
protein.
RESULTS
In vitro mitogenicity of the S34 mutant gp55
IL-3-dependent mouse pro-B-lymphoid Ba/F3 cells
were transfected by electroporation with pMER2-1 plas-
mid which expresses the mouse EpoR cDNA and the
neoR gene. After selection with G418 and subsequent
culture in the presence of Epo (2 U/ml) instead of IL-3, we
obtained a cell line (BER28C) which could grow in the
presence of either IL-3 or Epo but could not grow in the
absence of these factors. We then cotransfected BER28C
cells by electroporation with pSV2bsr encoding the BS-
resistance gene and either the wild-type F-SFFVp DNA or
the mutant F-SFFV DNA encoding the S34 mutant gp55.
Transfection and selection for BS-resistant cells were
carried out in the culture containing IL-3 but not Epo.
BS-resistant cells were obtained as cell populations
which grew in individual wells of microtiter plates. Each
cell population was then maintained separately in the
presence of IL-3.
Expression of gp55 by the BS-resistant cell popula-
tions was determined by Western blotting and the inten-
sity of the bands was quantified by densitometry. Of 44
independent BS-resistant cell populations obtained after
cotransfection with the mutant F-SFFV DNA, 37 showed
expression of the S34 mutant gp55 at various levels.
These positive cells were adapted to culture in the pres-
ence of Epo and in the absence of IL-3 and then exam-
ined for growth in the absence of Epo. Regardless of the
relative amount of gp55 expressed, these cells did not
show growth at all in the absence of the factors (Fig. 1B).
On the other hand, many of the 43 independent BS-
resistant BER28C cell populations which expressed the
wild-type gp55 showed significant growth in the absence
of the factors. The extent of growth determined by the
relative number of surviving cells after 3 days of culture
in the absence of the factors showed a roughly positive
correlation to the relative amount of gp55 detected (Fig.
1A). Each cell population may have consisted of both the
BS-resistant gp55-positive and BS-resistant gp55-nega-
tive cells, and only the former cells should have prolifer-
ated in the absence of the factors. The amount of gp55
detected would represent a proportion of the BS-resis-
tant gp55-positive cells. In accordance with this, growing
cells after the prolonged culture in the absence of the
factors demonstrated an enhanced level of wild-type
gp55 in the Western blotting analysis (data not shown).
These cells grew well in the absence of the factors and
the addition of Epo (up to 10 U/ml) did not stimulate
growth further (data not shown). We could not obtain
growing cells when S34 mutant gp55-expressing
BER28C cells were subjected to prolonged culture in the
absence of the factors.
EpoR binding by the S34 mutant gp55
Complex formation between the S34 mutant gp55 with
EpoR was investigated by co-immunoprecipitation fol-
lowed by detection of gp55 and EpoR in the precipitate
by Western blotting. Cell lysates were prepared from the
BER28C cells expressing either the wild-type gp55 (cell
population No. W45, Fig. 1A) or the S34 mutant gp55 (cell
population No. MA21, Fig. 1B) and subjected to immuno-
precipitation by goat anti-R-MuLV gp70 serum. Western
blotting detection of gp55 and EpoR in the precipitate is
shown in Fig. 2 (A and B). Goat anti-gp70 serum precip-
itated an almost equal amount of unprocessed gp55 from
W45 and MA21 cell lysates (Fig. 2A, lanes 2 and 3,
respectively). A small amount of gp55P was also de-
tected in the W45 cell lysate (lane 2). Quantification by
densitometry showed the ratio in intensity between the
wild-type unprocessed gp55 band and the S34 mutant
gp55 band was 1:0.76. No gp55 band was detected after
immunoprecipitation of the control BER28C cell lysate
(Fig. 2A, lane 1). Minor bands were observed migrating
slightly faster than the unprocessed gp55 bands of both
the wild-type and the S34 mutant. These minor bands
may be due to underglycosylated gp55 peptides.
Western blotting using anti-EpoR antibody revealed
co-immunoprecipitation of the EpoR peptides of 64 and
62 kDa in the case of the W45 cell lysate (Fig. 2B, lane 5),
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while only very faint 64- and 62-kDa bands could be
detected in the precipitate from the MA21 cell lysate
(lane 6). Densitometric analysis indicated the ratio in
band intensity, namely, that detected in the precipitate
from the W45 cell lysate vs that detected in the precipi-
tate from the MA21 cell lysate, as 1:0.027 for the 64-kDa
band and 1:0.044 for the 62-kDa band. No 64- and 62-kDa
bands could be detected in the precipitate from the
BER28C cell lysate (Fig. 2B, lane 4). Efficiency of co-
immunoprecipitation of EpoR by gp55 was estimated by
normalizing the amount of precipitated EpoR by the
amount of precipitated gp55. The ratio of efficiency of
co-immunoprecipitation (wild-type gp55 vs S34 mutant
gp55) was 1:0.036 for the 64-kDa EpoR peptide and
1:0.058 for the 62-kDa EpoR peptide, indicating that the
S34 mutant gp55 binds to the EpoR peptides with 4–6%
the efficiency of that of the wild-type gp55. We confirmed
that almost equal amounts of EpoR peptides (66, 64, and
62 kDa) are expressed in W45 and MA21 cells as well as
in BER28C cells as revealed by Western blotting of the
cell lysates by anti-EpoR antibody without prior immuno-
precipitaion by goat anti-gp70 serum (Fig. 2B, lanes 2, 3,
and 1, respectively).
Complex formation between gp55 and EpoR was also
analyzed by immunoprecipitation with the anti-EpoR an-
tibody and detection of gp55 in the precipitate by West-
ern blotting (Fig. 2C). From the wild-type gp55-express-
ing BER28C cells (cell populations W45 and W45S), anti-
EpoR antibody co-immunoprecipitated unprocessed and
also a processed higher molecular weight form of gp55
(gp55P) (lanes 2 and 3). This is the first direct demon-
stration of the complex formation between gp55P and
EpoR. Co-immunoprecipitation of the unprocessed S34
mutant gp55 was observed (lane 4), but only at a signif-
icantly reduced level compared to the wild-type. No
higher molecular weight form of S34 mutant gp55 was
detected in the precipitate. Densitometric measurement
indicated that the co-immunoprecipitation efficiency of
the unprocessed S34 mutant gp55 was 7.3% of that of the
wild-type gp55 (W45) when taking into account the level
of expression of gp55. We confirmed that almost an
equal amount of EpoR was immunoprecipitated from
different cell lysates (data not shown).
Disulfide-bonded dimer formation of the S34 mutant
gp55
We previously reported that the S34 mutant gp55 is
processed to the cell surface very poorly (Watanabe et
al., 1995). Since the wild-type gp55 exists as monomers
and also as a small number of heterogeneous ho-
modimers in the RER and the higher molecular weight
plasma membrane form of gp55 (gp55P) exists as a
homogeneous homodimer (Gliniak and Kabat, 1989; Kil-
patrick et al., 1989), the S34 mutant gp55 may not form a
specific homodimer in the RER which is competent for
transport to the cell surface via the Golgi apparatus.
Thus we examined the extent of dimer formation of the
S34 mutant gp55 in the RER.
Both MA21 and W45 cell lysates were immunoprecipi-
tated by goat anti-gp70 serum and the precipitates were
subjected to SDS–PAGE in the presence or the absence
of the reducing agent (2ME) and to Western blotting
using the 7C10 antibody. The results are shown in Fig. 3.
Under the reducing condition, unprocessed monomer
gp55s migrated as 52-kDa (W45 cell lysate) and 55-kDa
FIG. 1. Factor-independent growth of BER28C cell populations ex-
pressing either the wild-type (A) or the S34 mutant gp55 (B). Each point
in the figure represents a particular cell population and is plotted
according to the relative amount of gp55 which it expresses (abscissa)
and the level of factor-independent growth (ordinate). The relative
amount of gp55 was determined by Western blotting analysis of the
lysate of cells which were grown in the presence of IL-3 and subse-
quent densitometry and expressed in the figure relative to the level (i.e.,
100) found in the 14-1 NIH 3T3 cells which express the wild-type gp55.
Factor-independent growth is expressed by the ratio (in percentage) of
cell numbers measured by the MTT method after 3 days of culture in
the absence or the presence of Epo (2 U/ml). The arrow in A indicates
the wild-type gp55-expressing cell population (W45) and the arrow in B
indicates the S34 mutant gp55-expressing cell population (MA21).
These cell populations were used for subsequent studies.
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(MA21 cell lysate) bands (Fig. 3A, lanes 2 and 3, respec-
tively). In addition, the processed plasma membrane
form (gp55P) was observed in the W45 cell lysate as a
faint band having a 62-kDa molecular mass. Under non-
reducing conditions, besides the unprocessed monomer
gp55s which migrated significantly faster than those un-
der the reducing conditions, higher molecular weight
bands could be observed in both W45 and MA21 cell
lysates (Fig. 3B, lanes 2 and 3, respectively). The appar-
ent molecular mass of this band of the W45 cell lysate
was 89 kDa, which was about twice as large as that of
the monomer band (i.e., 47 kDa), and the apparent mo-
lecular mass of the higher molecular weight band of the
MA21 cell lysate was 117 kDa, which was also about
twice as large as that of the monomer band (i.e., 51 kDa).
These results suggest that these higher molecular
weight bands are disulfide-bonded homodimers of the
respective unprocessed gp55. Quantification of the in-
tensities of these monomer and dimer gp55 bands by
densitometry showed that while equivalent amounts of
monomer gp55 are detected in W45 and MA21 cell ly-
sates, the amount of dimer of the S34 mutant gp55 is 34%
of that of the wild-type gp55, indicating that the S34
mutant gp55 forms disulfide-bonded homodimers in the
RER significantly less efficiently than the wild-type gp55.
In lane 2 of Fig. 3B, a very faint 140-kDa band appeared.
This band probably corresponds to the disulfide-bonded
wild-type gp55P homodimer.
Analysis of the disulfide-bonded oligomerization state
of gp55 bound to EpoR
We analyzed the disulfide-bonded oligomerization
state of gp55 which was co-immunoprecipitated by the
anti-EpoR antibody. The immunoprecipitates were sub-
jected to SDS–PAGE in the absence of 2ME and to
Western blotting using 7C10 antibody. As shown in Fig. 4
lanes 2 and 3, both the unprocessed monomer and
dimers were detected in the immunoprecipitates from
the wild-type gp55-expressing cells. The amount of
monomer was in large excess of that of the dimers. No
distinct bands corresponding to the gp55P monomer
were observed in these lanes. Considering the results
obtained by SDS–PAGE in the presence of 2ME and
Western blotting (Fig. 2C, lanes 2 and 3), bands corre-
sponding to the gp55P dimer should be present, which,
FIG. 2. Analysis of EpoR binding by the S34 mutant gp55. EpoR binding was measured by co-immunoprecipitation (IMP) followed by Western
blotting (WB) of the precipitates. (A) Immunoprecipitation by goat anti-R-MuLV gp70 serum and Western blotting using 7C10 rat anti-nonecotropic
MuLV gp70 monoclonal antibody of the lysates of the following cells: lane 1, BER28C; lane 2, BER28C cells transfected with the wild-type F-SFFV DNA
(W45); lane 3, BER28C cells transfected with the S34 mutant F-SFFV DNA (MA21). (B) Western blotting using M-20 rabbit anti-EpoR antibody of the
cell lysates without prior immunoprecipitation (lanes 1–3) and of the immunoprecipitates by the goat anti-gp70 serum (lanes 4–6): lanes 1 and 4,
BER28C; lanes 2 and 5, W45; lanes 3 and 6, MA21. (C) Immunoprecipitation by the M-20 anti-EpoR antibody and Western blotting using 7C10 rat
monoclonal antibody of the lysates of the following cells: lane 1, BER28C; lane 2, W45; lane 3, a cell population derived from W45 after prolonged
culture in the absence of the factors (W45S); lane 4, MA21. Molecular mass standards are indicated (in kilodaltons) on the left of each panel. A 52-kDa
band which appeared in lane 1 and probably in all other lanes in C is probably the rabbit IgG heavy chain that was used for immunoprecipitation
of EpoR.
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however, are not discernible due to the background
signals. In the immunoprecipitate from the S34 mutant
gp55-expressing cells, only a very faint band of unproc-
essed monomer gp55 was detected (Fig. 4, lane 4).
DISCUSSION
In the present study, we demonstrated that the S34
mutant gp55 of F-SFFV does not activate mouse EpoR in
an in vitro factor-independent cell proliferation assay,
even if the amount of protein expressed is at a level
similar to that of the wild-type gp55. We also showed that
there is a roughly positive correlation between the level
of expression of the wild-type gp55 and the degree of
abrogation of factor-dependency of Ba/F3 cells express-
ing EpoR. These results confirm in a quantitative manner
that F-SFFVp gp55 itself causes activation of the mouse
EpoR resulting in mitogenic signal transduction. In fact,
the level of expression of the S34 mutant gp55 was
generally slightly lower than that of the wild-type gp55
(Fig. 1). The reason for this is not clear. It is possible that
the high-level expression of a virus-encoded protein has
an adverse effect on cell growth. In case of wild-type
gp55-expressing cells, activation of EpoR occurs, which
may enhance the growth potential of BER28C cells even
in the presence of IL-3. In case of S34 mutant gp55-
expressing cells, EpoR activation does not occur, and
those cells expressing a high level of the mutant protein
may have been selected out. There are several cell
FIG. 3. Disulfide-bonded dimer formation of the S34 mutant gp55. Cell lysates were immunoprecipitated by goat anti-gp70 serum and
the precipitates were subjected to SDS–PAGE in the presence (A) or the absence (B) of the reducing agent (2ME) and to Western
blotting using the 7C10 antibody. Lane 1, BER28C; lane 2, BER28C cells transfected with the wild-type F-SFFV DNA (W45); lane 3,
BER28C cells transfected with the S34 mutant F-SFFV DNA (MA21). Molecular mass standards are indicated (in kilodaltons) between the
panels.
FIG. 4. Analysis of disulfide-bonded oligomerization state of
gp55 bound to EpoR. Cell lysates were immunoprecipitated by
the anti-EpoR antibody (M-20), and the immunoprecipitates
were subjected to SDS–PAGE in the absence of the reducing
agent (2ME) and to Western blotting using the 7C10 antibody.
Lane 1, BER28C; lane 2, BER28C cells transfected with the wild-
type F-SFFV DNA (W45); lane 3, a cell population derived from
W45 after prolonged culture in the absence of the factors (W45S);
lane 4, BER28C cells transfected with the S34 mutant F-SFFV DNA
(MA21). Molecular mass standards are indicated (in kilodaltons) on
the left.
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populations which express the S34 mutant gp55 at a
level of more than 80 (Fig. 1B). None of these cell pop-
ulations showed EpoR activation at all. On the other
hand, most cell populations expressing the wild-type
gp55 at a level of less than 80 showed a low level of
activation (Fig. 1A). It was below 10%, but not 0%. We
previously reported that the mutant F-SFFV encoding the
S34 mutant gp55 was nonpathogenic in adult mice (Wa-
tanabe et al., 1995). The present study showing inability
of the S34 mutant gp55 to activate EpoR is consistent
with the proposal that EpoR activation is a prerequisite
for F-SFFVp gp55 to cause pathogenesis in mice.
Since the S34 mutant gp55 is a domain-addition mu-
tant protein and its primary structure is very similar to
that of the wild-type gp55, we thought that comparison of
the biochemical properties of this mutant protein with
those of the wild-type protein provided information about
the biochemical mechanism of function of the wild-type
protein. By the co-immunoprecipitation assay using ei-
ther anti-gp70 antibody or anti-EpoR antibody, we found
that the S34 mutant gp55 hardly binds to the EpoR. The
amount of complex formed between the S34 mutant gp55
and EpoR was less than 10% of that formed between the
wild-type gp55 and EpoR when the expression levels of
these proteins were taken into account. The S34 mutant
gp55 formed disulfide-bonded homodimers in the RER
much less efficiently than the wild-type gp55. This ex-
plains the reduced level of processing of this mutant
protein through the Golgi apparatus to the cell surface
considering that only a specific type of homodimer is
competent for export from the RER (Gliniak and Kabat,
1989). The S34 mutant protein may not form this specific
type of homodimer in the RER. In addition, we thought of
the possibility that the reduced level of homodimer for-
mation in the RER is the cause of the inability of the S34
mutant gp55 to bind to EpoR. This assumption is based
on the hypothesis that only a certain kind of homodimer
binds to EpoR in the RER. To test this hypothesis, we
examined the disulfide-bonded oligomerization state of
the wild-type gp55 which was bound to EpoR in the RER.
The results showed that both monomers and ho-
modimers of the wild-type gp55 are bound to EpoR in the
RER. Thus, it appears that the inability of the S34 mutant
gp55 to bind to EpoR is unrelated to its defect in the
homodimer formation in the RER. Unprocessed mono-
mers of the S34 mutant gp55 are incapable of binding to
EpoR. If we compare the disulfide-bonded oligomeriza-
tion of the total wild-type unprocessed gp55 with that of
the wild-type unprocessed gp55 bound to EpoR, it is
evident that the proportion of homodimer is increased
about twofold in gp55 bound to EpoR over that in the total
gp55 (Figs. 3B, lane 2, and 4, lane 2). This may mean that
although both monomers and homodimers of the wild-
type unprocessed gp55 bind to EpoR, these are not
equal in their binding ability to EpoR. Alternatively, it is
possible that the binding of EpoR to an unprocessed
monomer gp55 molecule facilitates the homodimer for-
mation of gp55.
Due to the additional cytoplasmic domain which may
cause steric hindrance or a transmembrane effect on the
conformation of the extracytoplasmic domain, the S34
mutant gp55 monomers associate poorly with each
other, resulting in a lack of the specific type of ho-
modimer and a defect in processing to the cell surface.
Also, by the same reasoning, monomers of the S34
mutant gp55 do not form a complex with EpoR efficiently.
It is possible that the additional cytoplasmic domain may
affect the interaction with an unidentified protein which
may mediate association of gp55 with EpoR. One base
pair insertion in the gp55 gene causing a truncation of
the MuLV env p15E-derived cytoplasmic domain is es-
sential for pathogenicity in that it makes the encoded
protein competent for both binding to EpoR and process-
ing to the cell surface.
MATERIALS AND METHODS
Material
Recombinant human erythropoietin (rh-Epo, 2.61 3 105
IU/mg protein) was produced by Chinese hamster ovary
cells and kindly supplied by Chugai Phamaceutical Co.
Cell culture
Interleukin-3 (IL-3)-dependent mouse pro-B-lymphoid
cells Ba/F3 (Mathey-Prevot et al., 1986) were cultured in
RPMI 1640 medium, supplemented with 10% fetal bovine
serum (FBS), 50 mM 2-mercaptoethanol (2ME), and 1% of
the conditioned medium of MIL34 cells which secrete
murine IL-3, at 37°C in humidified 5% CO2/95% air.
Preparation of EpoR-expressing Ba/F3 cells
Ba/F3 cells were transfected by electroporation with
the pMER2-1 plasmid which expresses EpoR cDNA and
the neomycin-resistance (neoR) gene (Chiba et al., 1993).
Briefly, the circular form of the plasmid DNA (30 mg) was
mixed with Ba/F3 cells (9.8 3 106 cells) in serum-free
RPMI 1640 medium. The cell suspension (0.8 ml) was
kept on ice for 10 min and subjected to electroporation
(Gene Pulser, Bio-Rad) at 500 mF and 380 V. After elec-
troporation, the cells were plated in 24-well multiwell
plates at 5 3 104 cells/ml (1 ml/well) and selected for
growth in the presence of G418 (1 mg/ml) and IL-3.
G418-resistant Ba/F3 cells in several wells were recov-
ered separately and then cultured in the presence of Epo
(2 U/ml) and in the absence of IL-3. One of these cell
populations (BER28C) was chosen and used for subse-
quent experiments. BER28C cells showed Epo- or IL-3-
dependent growth and were routinely maintained in the
presence of IL-3 and G418.
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F-SFFV DNA transfection
BER28C cells cultured in the medium containing IL-3
were cotransfected by electroporation with pSV2bsr,
which encodes the blasticidine S (BS)-resistant gene
(Izumi et al., 1991), and a plasmid harboring either the
polycythemia-inducing wild-type or the S34 mutant F-
SFFV DNA (Watanabe et al., 1995). Electroporation was
performed using buffer consisting of 21 mM HEPES–
NaOH (pH 7.05), 137 mM NaCl, 5 mM KCl, 0.7 mM
Na2HPO4, and 6 mM glucose. Plasmid DNAs were used
after linearization with an appropriate restriction enzyme
which cut the plasmid in the vector sequence. Amounts
of 10–20 mg pSV2bsr and 50–100 mg F-SFFV plasmid
were used. After electroporation at 960 mF and 310 V,
the cells were kept at room temperature for 10 min and
then cultured in the presence of IL-3 and G418. Selection
with BS (15 mg/ml) was started 2 days after electropora-
tion. Cells were plated at 5 3 104 cells/ml in 24-well
multiwell plates (1 ml/well) in medium containing IL-3,
G418, and BS.
Western blotting analysis to detect gp55
BS-resistant cell populations were examined for ex-
pression of gp55 by Western blotting (Amanuma et al.,
1989). Cells were harvested and lysed in the lysing so-
lution consisting of 2% sodium dodecyl sulfate (SDS) and
0.5 mM phenylmethylsulfonyl fluoride in phospate-buff-
ered saline (PBS) and immediately boiled for 5 min.
Lysate containing 30 mg protein was subjected to SDS–
polyacrylamide gel electrophoresis (SDS–PAGE) (8%
acrylamide), and proteins were electrophoretically trans-
fered to a polyvinylidene fluoride membrane. After treat-
ing with blocking solution, proteins were reacted with
7C10 rat anti-nonecotropic MuLV gp70 monoclonal anti-
body (ascites fluid) (Wolff et al., 1982) (kindly provided by
Dr. S. Ruscetti, NCI-Frederick) and then with horseradish
peroxidase (HRP)-conjugated goat anti-rat IgG (TAGO,
Inc.), and finally the reacting bands were visualized by
treating with an enhanced chemiluminescence (ECL) de-
tection system (Amersham) and by exposure to X-ray film
(Kodak XAR-5). The intensities of the gp55 bands were
quantified using the Bio Image system (MilliGen/Bio-
search). As a positive control, a cell lysate of the 14-1
NIH 3T3 cells which express wild-type gp55 (Amanuma
et al., 1989) was used, and as a negative control, a lysate
of BER28C cells was used.
Factor-independent growth assay
BS-resistant cell populations expressing either the
wild-type or the S34 mutant gp55 were first adapted to
culture containing, in addition to G418 and BS, Epo (2
U/ml) instead of IL-3. These cells were then subcultured
under two different conditions: one in the presence of
Epo (2 U/ml) and the other in the absence of the factors.
Cells were plated in 24-well multiwell plates at a cell
density of 3.3 3 104 cells/ml (0.3 ml/well) in medium
without 2ME. Three days later, relative numbers of grow-
ing cells were estimated by the 3-(4, 5-dimethylthiazol-2-
yl)-2, 5-diphenyltetrazolium bromide (MTT) method (Mos-
mann, 1983) as follows. To the cells in each well, 30 ml of
MTT (Sigma) (5 mg/ml in PBS) was added. After incuba-
tion for 3 h at 37°C, 1 vol of acid–isopropanol (0.04 N
HCl/isopropanol) was added and mixed by pipetting.
Reduction of the reagent was determined by measuring
OD 570 and 630 nm. Factor-independent growth was
calculated as follows: (MTT reduced by cells growing in
the absence of the factors)/(MTT reduced by cells grow-
ing in the presence of Epo) 3 100 (%).
BS-resistant cell populations which expressed the
wild-type gp55 and grew after a prolonged culture in the
absence of the factors were examined for dependency of
growth on Epo. These cells were plated and measured
for growth by the MTT method as described above in the
absence and the presence of various concentrations of
Epo (from 0.03 to 10 U/ml). BER28C cells were used as a
control.
EpoR binding by gp55
Immunoprecipitation followed by Western blotting was
employed to measure binding of gp55 to EpoR (Li et al.,
1995). Cells cultured in the presence of IL-3 were har-
vested and washed twice with RPMI 1640 medium with-
out FBS and the pellet containing 5 3 106 cells was
dissolved in 1 ml of a lysis buffer consisting of 20 mM
Tris–HCl (pH 7.6), 0.5% Nonidet P-40, 0.5 M NaCl, 1 mM
EDTA, and a protease inhibitor mixture (13) (Complete,
Boehringer Mannheim) at 4°C for 30 min. This solution
was centrifuged at 10,000 g for 10 min at 4°C and the
supernatant was recovered and stored at 280°C. The
amount of protein was determined by using the BCA
protein assay reagent kit (Pierce). The cell lysate usually
contained about 1 mg/ml protein.
One milliliter of cell lysate was used for immunopre-
cipitation. All procedures described below were car-
ried out at 4°C. The cell lysate was first precleared by
10 ml of normal goat serum (Vector Laboratories) and
50 ml of a 50% (v/v) suspension of protein A–Sepha-
rose CL-4B (Pharmacia). To the precleared lysate, 10
ml of goat anti-Rauscher MuLV (R-MuLV) gp70 serum
which has a broad immunospecificity against the
MuLV env glycoproteins (obtained from the NCI) was
added and incubated for 2 h, and then 50 ml of 50%
(v/v) suspension of protein A–Sepharose CL-4B was
added and incubated for 1 h. Immunoprecipitates were
washed five times with 1 ml of the lysis buffer (without
Complete), suspended in 40 ml of SDS–sample buffer
(23), and boiled for 5 min. Half of the supernatant was
then subjected to Western blotting to detect gp55 or
EpoR. For gp55, 7C10 antibody was used as the first
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antibody and the reacting bands were detected by
the method as described above. For EpoR, rabbit
polyclonal IgG raised against the C-terminal 20-
amino-acid peptide of the mouse EpoR (M-20, Santa
Cruz Biotechnology, Inc.) was used as the first anti-
body, and the bands were visualized by treatment with
HRP-conjugated goat anti-rabbit IgG (Bio-Rad) and
ECL detection system and by exposure to an X-ray
film.
The cell lysate was also subjected to Western blotting
to detect EpoR without prior immunoprecipitation. For
this, a cell lysate containing 10 mg protein was used.
EpoR binding by gp55 was also analyzed by immuno-
precipitation by the M-20 antibody followed by Western
blotting of the precipitates to detect gp55 and EpoR. In
this case, cell lysates were prepared at 2 3 107 cells/ml
of the lysis buffer. Immunoprecipitation was carried out
using 5 ml cell lysate and 20 ml M-20 antibody for 12 h.
After washing, the immunoprecipitates were solubilized
by boiling in 50 ml of SDS–sample buffer (23), and the
supernatant was subjected to Western blotting using
either the 7C10 or the M-20 antibody.
Detection of disulfide-bonded dimer of gp55
Disulfide-bonded dimer formation of gp55 was ana-
lyzed by the method essentially as described previ-
ously (Gliniak et al., 1991). Briefly, cell lysates were
prepared and immunoprecipitated by goat anti-R-
MuLV gp70 serum as described above. Half of the
immunoprecipitate was solubilized by boiling in the
usual SDS–sample buffer containing 5% 2ME and the
other half was solubilized in SDS–sample buffer with-
out 2ME. Samples were subjected to SDS–PAGE (8%
acrylamide) and Western blotting as described above
by using 7C10 antibody.
Analysis of disulfide-bonded oligomerization state of
gp55 bound to EpoR
Immunoprecipitation of cell lysates by the M-20 anti-
body was carried out as described above. After washing,
the precipitates were solubilized in 50 ml of SDS–sample
buffer (23) without 2ME. The supernatants were ana-
lyzed by Western blotting using the 7C10 antibody.
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